Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at rapid speed.

Eli Lilly said the treatment, a once-daily pill called muvalaplin, showed reductions in Lp (a) levels compared to placebo. Injectables are currently in Phase 3 development, but "these are the first ...

On Friday, Eli Lilly And Co (LLY) stock saw a decline, ending the day at $746.2 which represents a decrease of $-40.03 or -5.09% from the prior close of $786.23. The stock opened at $775.19 and ...

The highest dose of an experimental pill developed by Eli Lilly dramatically lowered an inherited form of high cholesterol in ...

The new mens range debuted at a VIP fashion show in Palm Beach last week, and will arrive in stores in February for the ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

Evercore ISI analyst Umer Raffat maintained a Hold rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last ...

Barclays analyst Carter Gould maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $975.00.

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr.